Abstract Background and Objective The influence of glycemic control on cardiovascular (CV) complications or survival is not clear in diabetic patients with end-stage renal disease (ESRD
Introduction

In diabetic patients, glycemic control has an essential role in preventing the development and progression of microvascular or cardiovascular (CV) complications (1-4). Glycohemoglobin (HbA1c) is the most representative marker of hyperglycemia for assessing glycemic control. In diabetic patients with end-stage renal disease (ESRD), there are two unresolved and important problems. First, it is not clear whether glycemic control reduces the risk of cardiovascular complications or mortality. Second, it is not clear whether
HbA1c is a reliable marker of hyperglycemia (5) .
Only a few studies have shown beneficial impact of predialysis glycemic control on survival after initiation of dialysis (6, 7) . In addition, limited studies showed an association of poor glycemic control with poor survival on chronic dialysis (8, 9) . However, several studies showed no correlation
T a b l e 1 . P a t i e n t Ch a r a c t e r i s t i c s
between glycemic control and survival (10, 11) 
. Therefore, the significance of glycemic control is not established and appropriate targets of glycemic control have not yet been determined in diabetic ESRD patients.
HbA1c level is influenced by erythrocyte lifespan or erythropoietin therapy (12, 13) (14) . GA levels may reflect blood glucose levels more correctly in ESRD patients (15) . There have been no previous studies concerning the relation between GA levels and the prognosis in these patients.
. Shortened erythrocyte lifespan or erythropoietin therapy changes HbA1c levels independent of glycemic control. It is generally known that HbA1c levels tend to be lower in ESRD patients. Glycated albumin (GA) is an alternative marker of glycemic control and is not influenced by erythrocyte lifespan or erythropoietin therapy
To clarify the association between glycemic control and clinical outcome in diabetic ESRD patients, we obtained both HbA1c and GA levels simultaneously on chronic dialysis and examined the association with prognosis. In addition, we also obtained HbA1c levels at initiation of dialysis and examined the association with prognosis. 
Subjects and Methods
Results
Survival and development of CV complications
The 1-, 3-and 4- Relationship between HbA1c2 and GA2 levels are shown in Fig. 1 . The correlation coefficients between HbA1c2 and GA2 levels, those between HbA1c2 and blood glucose levels, and those between GA2 and blood glucose levels were F i g u r e 1 . Co r r e l a t i o n b e t we e n Hb A1 c 2 a n d GA2 . (Fig. 2) . The cases of HbA1c1 were the same. There were also no significant differences in mortality between the higher GA2 (GA 23.0%) group and the lower GA2 (GA < 23.0%) group (Figs. 3a, 3b) . On the other hand, CV diseases developed in 15 patients in the higher GA2 group (n=39) and in 5 patients in the lower GA2 group (n=39). The higher GA2 group had a significant higher rate of development of CV diseases than the lower GA2 group (Fig. 3c) 
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F i g u r e 2 . T h e Ka p l a n -Me i e r s u r v i v a l c u r v e s o f a l l -c a u s e mo r t a l i t y ( a ) , CV mo r t a l i t y ( b ) a n d d ev e l o p me n t o f CV d i s e a s e s ( c ) i n t h e h i g h e r Hb
F i g u r e 3 . T h e Ka p l a n -Me i e r s u r v i v a l c u r v e s o f a l l -c a u s e mo r t a l i t y ( a ) , CV mo r t a l i t y ( b ) a n d d ev e l o p me n t o f CV d i s e a s e s ( c ) i n t h e h i g h e r GA2 ( GA≧ 2 3 . 0 %) g r o u p a n d t h e l o we r GA2 ( GA＜ 2 3 . 0 %) g r o u p .
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Effect of changes in HbA1c levels on prognosis
We divided subjects into two groups according to the changes between HbA1c1 and HbA1c2 levels. In the general population or in diabetic patients without renal dysfunction, the association between glucose levels and CV complications or survival was demonstrated in some previous studies (17) (18) (19) (23) (24) (25) . Therefore, the direct influence of hyperglycemia on fatal CV diseases might be small in these patients. (5, 13) . Some previous studies showed a weak correlation between HbA1c levels and mean blood glucose levels in diabetic ESRD patients (11, 13, 15 (13, 14) .
. However, diabetic ESRD patients have already advanced atherosclerosis (20, 21). In addition to hyperglycemia, there are many risk factors associated with CV diseases, including traditional factors and uremiarelated factors in diabetic ESRD patients (22). Some previous studies have demonstrated that increased all-cause mortality or CV mortality are associated with advanced atherosclerosis independent of diabetes in ESRD patients
Non-CV diseases such as infectious diseases or cancer may also influence the outcome in diabetic ESRD patients. Hyperglycemia impairs the host defense and increases the risk of infectious diseases (26). Diabetes increases the risk of cancer in some epidemiological studies (27). However, the influence of glycemic control on the development of infectious diseases or cancer is unclear in diabetic ESRD patients. Our results could not find these associations. The registry data of the Japanese Society for Dialysis Therapy also showed no significant differences of frequency of infectious diseases or cancer as causes of death between diabetic patients and non-diabetic patients (28). The direct influence of hyperglycemia on the progression of atherosclerosis or development of CV diseases is not clear in diabetic ESRD patients. Our results showed an association between hyperglycemia, reflected by higher GA levels and development of CV diseases. Several mechanisms of toxic effects of hyperglycemia have been demonstrated, including endothelial dysfunction, oxidative stress, inflammation, formation of glycation products, and abnormal coagulation (29, 30). It is not clear whether these mechanisms influence the progression of atherosclerosis or development of CV diseases in ESRD patients as in general diabetic
One previous study showed that GA levels might reflect blood glucose levels more correctly than HbA1c levels in ESRD patients (15) 
